KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Change in Receivables (2016 - 2017)

Historic Change in Receivables for Gsk (GSK) over the last 9 years, with Q4 2017 value amounting to -$381.0 million.

  • Gsk's Change in Receivables fell 6302.86% to -$381.0 million in Q4 2017 from the same period last year, while for Dec 2017 it was $83.7 million, marking a year-over-year decrease of 8293.47%. This contributed to the annual value of -$573.0 million for FY2018, which is 5496.85% down from last year.
  • Latest data reveals that Gsk reported Change in Receivables of -$381.0 million as of Q4 2017, which was down 6302.86% from -$233.7 million recorded in Q4 2016.
  • In the past 5 years, Gsk's Change in Receivables registered a high of $549.8 million during Q4 2014, and its lowest value of -$381.0 million during Q4 2017.
  • Its 5-year average for Change in Receivables is $21.9 million, with a median of $25.9 million in 2013.
  • Its Change in Receivables has fluctuated over the past 5 years, first skyrocketed by 202230.9% in 2014, then tumbled by 25716.45% in 2016.
  • Quarter analysis of 5 years shows Gsk's Change in Receivables stood at $25.9 million in 2013, then skyrocketed by 2022.31% to $549.8 million in 2014, then crashed by 72.95% to $148.7 million in 2015, then tumbled by 257.16% to -$233.7 million in 2016, then plummeted by 63.03% to -$381.0 million in 2017.
  • Its Change in Receivables was -$381.0 million in Q4 2017, compared to -$233.7 million in Q4 2016 and $148.7 million in Q4 2015.